摘要
目的评价应用预混胰岛素治疗血糖控制不佳的T2DM患者转换为甘精胰岛素联合口服药物治疗的有效性及安全性。方法选择62例应用预混胰岛素治疗但血糖控制不佳的T2DM患者,将其治疗方案转换为甘精胰岛素联合口服药治疗16周。以治疗前后FPG、2hPG及HbA1c的变化评价方案的有效性和低血糖发生率及BMI的变化评价治疗的安全性,采用调查问卷评分比较治疗前后满意度。结果治疗16周后,FPG、2hPG及HbA1c较治疗前下降(P<0.01),HbA1c下降幅度大于1%者占63.79%;治疗期间共有16例发生非重度日间低血糖27次;患者对治疗的满意度较治疗前增加(P<0.01)。结论应用预混胰岛素治疗但血糖控制不佳的T2DM患者转换为甘精胰岛素联合口服药物治疗具有安全性、有效性。
Objective To evaluate the efficacy and safety of oral hypoglycemic agents plus glargine insulin（OHAs） switched from premixed insulin in T2DM with poorly controlled blood glucose.Methods A total of 62 T2DM patients whose blood glucose were inadequately controlled with premixed insulin were enrolled in this study.Their treatment was switched from premixed insulin to glargine insulin plus OHAs and a follow-up for 16 weeks was conducted.The efficacy was assessed by FPG,2 hPG,and HbA1c.The safety was evaluated by the incidence of hypoglycaemia and the changes of BMI.The satisfaction of patients was also investigated by the questionnaire scores.Results After 16 weeks follow-up,the FPG,2 hPG,and HbA1c were decreased significantly（P0.01）.HbA1c decreased by more than 1%,accounting for 63.79% of the patients.A total of 27 times minor hypoglycaemia were observed in 16 patients in daytime during the follow-up.The patients were more satisfied than before（P0.01）.Conclusion Switching from premixed insulin（with or without OHAs） to glargine insulin plus OHAs is safe and effective.
出处
《中国糖尿病杂志》
CAS
CSCD
北大核心
2013年第2期160-162,共3页
Chinese Journal of Diabetes
基金
"十一五"国家科技支撑计划项目(2006BAI02B08)
国家科技支撑计划(2009BAI80B04)
中华医学会糖尿病学分会重点项目(07020470055)
山东省医药卫生科技发展计划项目(2011HD005)
山东省科技攻关国际科技合作项目(2010GHZ20201)
济南市科技局科技明星项目(20100318)
山东大学自主创新基金(2009TS054)
关键词
糖尿病
2型
预混胰岛素
甘精胰岛素
糖化血红蛋白
Diabetes mellitus
type 2
Premixed insulin
Glargine insulin
Glycosylated hemoglobin（HbA1c）
